Jose Bazan, M.D., M.S. | City of Hope

Dr. Jose G. Bazan

Claim this profile

Ohio State University Comprehensive Cancer Center

Studies Breast Cancer
Studies Breast cancer
7 reported clinical trials
15 drugs studied

Area of expertise

1

Breast Cancer

Jose G. Bazan has run 6 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
Stage I
2

Breast Cancer

Jose G. Bazan has run 4 trials for Breast cancer. Some of their research focus areas include:

Stage IV
ER positive
Stage II

Affiliated Hospitals

Image of trial facility.

Ohio State University Comprehensive Cancer Center

Image of trial facility.

City Of Hope Medical Center

Clinical Trials Jose G. Bazan is currently running

Image of trial facility.

SBRT and Imaging

for Metastatic Breast Cancer

This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (oligoprogression). Currently, the standard of care for breast cancer patients with oligoprogressive disease is to change systemic therapy when progression occurs. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses (fractions) given over several days. This type of radiation therapy helps spare normal tissue and has been shown to improve survival. SBRT may kill more tumor cells and allow patients with oligoprogressive ER + metastatic breast cancer to continue taking current systemic treatment. This trial also tests how well ER targeted positron emission tomography (PET)/ computed tomography (CT) imaging, using FES, works in identifying progressive disease in patients with ER + metastatic breast cancer. FES, a radiolabeled substance, binds to estrogen receptors and gives off radiation that can be detected by a PET scan. The PET scan, an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, FES, forms an image that shows where tumor cells with estrogen receptors can be found in the body. CT images use x-rays to provide an exact outline of organs. FES PET/CT may improve identification of progressive disease in patients with ER + metastatic breast cancer.

Recruiting

1 award

Phase 2

Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

More about Jose G. Bazan

Clinical Trial Related

2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jose G. Bazan has experience with

  • F-18 16 Alpha-Fluoroestradiol
  • Stereotactic Body Radiation Therapy
  • Berzosertib
  • Radiation Therapy
  • Docetaxel
  • Gemcitabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jose G. Bazan specialize in?

Is Jose G. Bazan currently recruiting for clinical trials?

Are there any treatments that Jose G. Bazan has studied deeply?

What is the best way to schedule an appointment with Jose G. Bazan?

What is the office address of Jose G. Bazan?

Is there any support for travel costs?